Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TechnologyAdvice

Biogen Idec building

Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults

Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases

- PMLiVE

Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn

Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for adults with urothelial carcinoma

UC accounts for approximately 90% of all bladder cancers, the ninth most common cancer globally

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for uncontrolled COPD

No new treatment approaches have been approved for the respiratory disease in more than a decade

- PMLiVE

Amgen’s interchangeable Soliris biosimilar Bkemv approved by FDA for rare blood disorders

Bkemv has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

Medical devices – the rapidly evolving landscape of healthcare and technology

How choosing market entry in one country over another can impact the success of your medical device

- PMLiVE

Through the looking-glass: AI in medical imaging

By Cathy Chow

- PMLiVE

Going deeper than the data: integrating neuromarketing for customer engagement

By Nicole Luciano

- PMLiVE

Medscape Oncology Launches Inaugural Medscape Fellows Program at ASCO 2024

Medscape Oncology is excited to announce the launch of the first-ever Medscape Fellows Program at the 2024 ASCO meeting in Chicago, Illinois. This groundbreaking program aims to nurture young oncology...

Medscape Education

- PMLiVE

AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study

Datopotamab deruxtecan demonstrated a clinically meaningful overall survival improvement in NSCLC patients

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

- PMLiVE

Merck presents positive results for Keytruda plus chemotherapy in breast cancer

Triple-negative breast cancer accounts for 24% of all newly diagnosed cancers worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links